May 29 – June 1, 2018
From the event website:
The meeting will include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry that will discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Marlene Freeman and John Newcomer with representation of the sectors that are part of the ASCP community lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2018 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Anita Clayton are responsible for the review of all program submissions.
MAPS Clinical Data Scientist Allison Feduccia, Ph.D., will give a 10-minute talk in the Pharmaceutical Pipeline Presentations entitled MDMA-Assisted Therapy for Treatment of Chronic Posttraumatic Stress Disorder (PTSD): Findings from Phase 2 Clinical Research Trials, co-authored by Feduccia, Lisa Jerome, Ph.D., Michael Mithoefer, M.D., Berra Yazar-Klosinski, Ph.D., Amy Emerson, B.S., and Rick Doblin, Ph.D.
For more information, visit the event website.